PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice.
Gastrointestinal (GI) absorption of certain therapeutic agents is thought to be mediated by solute carrier (SLC) transporters, although minimal in vivo evidence has been reported. Here, we show key roles of postsynaptic density 95/disk-large/ZO-1 (PDZ) domain-containing protein, PDZK1, as a regulatory mechanism of two solute carriers, Slc15a1 (oligopeptide transporter PEPT1) and Slc22a5 (carnitine/organic cation transporter OCTN2) in mouse small intestine by using pdzk1 gene knockout (pdzk1(-/-)) mice. GI absorption of cephalexin, a substrate of PEPT1, after p.o. administration was delayed in pdzk1(-/-) mice compared with wild-type mice. Absorption of carnitine, a substrate of OCTN2, was also decreased in pdzk1(-/-) mice. Immunohistochemical analysis revealed the localization of both PEPT1 and OCTN2 at apical membrane of small intestinal epithelial cells in wild-type mice, whereas such apical localization was reduced in pdzk1(-/-) mice, with a concomitant decrease in their protein levels assessed by Western blotting in intestinal brush-border membranes. Electron microscopy revealed localization of PEPT1 in intracellular vesicular structures in pdzk1(-/-) mice. In addition, we first identified interaction between PEPT1 and PDZK1 in mouse small intestine and found that PDZK1 stimulates transport activity of PEPT1 by increasing its expression level in human embryonic kidney 293 cells. Taken together, the present findings provide direct evidence that PDZK1 regulates two intestinal SLC transporters in vivo as an adaptor protein for these transporters and affects oral absorption of their substrates. These findings also raise the possibility that intestinal absorption of the substrate drugs for PEPT1 and OCTN2 is governed by the protein network of these transporters and their adaptor PDZK1.
Sugiura
Tomoko
T
Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, Ishikawa, Japan.
Kato
Yukio
Y
Wakayama
Tomohiko
T
Silver
David L
DL
Kubo
Yoshiyuki
Y
Iseki
Shoichi
S
Tsuji
Akira
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics; D002331:Carnitine / Q000097:blood / Q000493:pharmacokinetics; D002460:Cell Line; D002506:Cephalexin / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D007408:Intestinal Absorption; D007421:Intestine, Small / Q000378:metabolism* / Q000648:ultrastructure; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D018345:Mice, Knockout; D027701:Organic Cation Transport Proteins / Q000378:metabolism*; D000074011:Peptide Transporter 1; D012333:RNA, Messenger / Q000378:metabolism; D000074058:Solute Carrier Family 22 Member 5; D027981:Symporters / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D027701:Organic Cation Transport Proteins; C514896:PDZK1 protein, mouse; D000074011:Peptide Transporter 1; D012333:RNA, Messenger; C489941:Slc15a1 protein, mouse; C492019:Slc22a5 protein, mouse; D000074058:Solute Carrier Family 22 Member 5; D027981:Symporters; D002506:Cephalexin; D002331:Carnitine